RxDoctor Payments Data

Mehar Brar, PA

Physician Assistant · Chelsea, MINPI 1255004511

Payments from drug & device makers

$2,875in general payments, 2019–2025

Across 82 payments — averaging $35.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Medtronic$484
  • Sumitomo Pharma America, Inc.$335
  • AbbVie$159
  • Pharming Healthcare, Inc.$125
  • Astellas Pharma US Inc$48
  • plus $148 from 5 others

What the payments were for

  • Travel & lodging$1,18541%
  • Food & beverage$1,69159%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,875 in reported general payments places this provider in the 85th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$34,976
Medicare patients
156
Services billed
526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron101$59,509
GemtesaVibegron53$35,024
Trospium Chloride ErTrospium Chloride55$10,556
Estradiol86$8,829
Mirabegron ErMirabegron19$7,793
Methenamine Hippurate23$2,815
Fosfomycin Tromethamine13$1,600
Trospium Chloride14$1,278
Metronidazole26$886
Cephalexin237$828
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst84$654
Solifenacin Succinate15$498
Cefdinir23$450
Nystatin36$427
Clobetasol Propionate20$283

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$48$59,509101 claims
Sumitomo Pharma America, Inc.Gemtesa$335$35,02453 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Chelsea

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →